UK markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1602
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • BTC-GBP

    33,773.38
    -1,910.03 (-5.35%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Worldwide Multiple Sclerosis Therapeutics Industry to 2027 - by Drug Class, Route of Administration, and Distribution Channel and Geography

Research and Markets
·9-min read

Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class, Route of Administration, and Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global multiple sclerosis therapeutics market is expected to reach US$ 39,223.59 million by 2027 from US$ 24,026.90 million in 2019. The market is estimated to grow at a CAGR of 6.5% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.

Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in multiple sclerosis (MS) treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.

Based on route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.

Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This would be difficult, especially for developing countries across the globe, as it may lead to reduction in imports due to disruptions in global trade. Till date, no definitive treatment against COVID-19 has been established. Patients with severe health conditions, such as neurological diseases, are witnessing delays in treatment. Supply chain disruptions associated with this pandemic situation would ultimately affect the sales of products for a short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to stay open during the lockdown. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the COVID-19 pandemic.

Merck & Co., Inc.; Novartis AG; Bayer AG; Sanofi; Bristol-Myers Squibb Company; Horizon Therapeutics plc.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd., and Biogen are among the leading companies operating in the multiple sclerosis therapeutics market.

The report segments global multiple sclerosis therapeutics market as follows:

By Drug Class

  • Immunosuppressant

  • Immunomodulators

By Route of Administration

  • Injectable

  • Oral

By Distribution Channels

  • Hospital Pharmacies

  • Retail Pharmacies

  • E-Commerce

By Geography

  • North America

  • US

  • Canada

  • Mexico

  • Europe

  • France

  • Germany

  • Italy

  • UK

  • Spain

  • Rest of Europe

  • Asia Pacific (APAC)

  • China

  • India

  • South Korea

  • Japan

  • Australia

  • Rest of Asia Pacific

  • Middle East & Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Rest of Middle East & Africa

  • South America (SAM)

  • Brazil

  • Argentina

  • Rest of South America

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Multiple Sclerosis Therapeutics market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global Multiple Sclerosis Therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 Global Multiple Sclerosis Therapeutics Market - By Route Of Administration
1.3.3 Global Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 Global Multiple Sclerosis Therapeutics Market - By Geography

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South and Central America (SCAM) - PEST Analysis
4.1 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - Global Analysis
6.1 Global Multiple Sclerosis Therapeutics Market Revenue Forecast And Analysis
6.2 Global Multiple Sclerosis Therapeutics Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis And Forecast To 2027 - Geographical Analysis
10.1 North America: Multiple Sclerosis Therapeutics Market
10.2 Europe: Multiple Sclerosis Therapeutics Market
10.3 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Revenue And Forecasts To 2027
10.5 South and Central America: Multiple Sclerosis Therapeutics Market

11. Impact of COVID-19 Pandemic on Global Multiple Sclerosis Therapeutics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment Of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
11.5 South & Central America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Horizon Therapeutics plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Takeda Pharmaceutical Company Limited
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. HOFFMANN-LA ROCHE LTD.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Biogen
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/yb5oto

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900